Navigation Links
Jennerex Presents Positive Clinical Data from Phase 2 Trial of JX-594 in Sorafenib-Refractory Liver Cancer Patients
Date:9/17/2012

BERLIN, Sept. 17, 2012 /PRNewswire/ -- Jennerex, Inc., a private, clinical-stage biotherapeutics company focused on the development and commercialization of first-in-class targeted oncolytic immunotherapies, presented Phase 2 clinical data of JX-594 delivered first intravenously and subsequently through intra-tumoral route demonstrating safety as well as disease control and tumor responses in patients with hepatocellular carcinoma (liver cancer, HCC).  The data were presented in an oral presentation at the International Liver Cancer Association (ILCA) Annual Meeting in Berlin, Germany, by Mong Cho, M.D., from Pusan National University Yangsan Hospital, South Korea.

Twenty five Asian patients with advanced HCC, 20 of whom were refractory to sorafenib, were treated with an initial intravenous dose of JX-594, and the majority of patients then received sequential intra-tumoral doses of JX-594 at week one and three. The majority of patients subsequently received treatment with sorafenib.

The primary objective of this study was to determine the safety of JX-594 followed by sorafenib in patients with advanced HCC. The sequential treatment regimen was well tolerated with transient flu-like symptoms and transient leukopenia being the most common side effects related to JX-594.  The sorafenib side effects observed were consistent with the expected toxicity profile of this product.

Secondary endpoints included the effect of the sequential treatment of JX-594 followed by sorafenib on disease control and tumor response. Evidence of antitumor activity was observed in both sorafenib-naive and sorafenib-refractory patients. 

Importantly, this trial also demonstrated the feasibility of the systemic administration of the product (through intravenous injection).

"Our ability to deliver JX-594 intravenously to liver cancer tumors, further confirmed by these encouraging data, is a key attribute that sets it apart from other thera
'/>"/>

SOURCE Jennerex, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Jennerex Announces First Patient Treated in Phase 2 Clinical Trial of Intravenous Delivery JX-594 In Patients with Advanced Liver Cancer
2. Jennerex Appoints Dr. Laurent Fischer as President and Chief Executive Officer
3. Sorbent Therapeutics Presents CLP1001 Phase 2a Study Results at the 16th Annual Meeting of the Heart Failure Society of America
4. Mettler Toledo Presents In-depth Guidance to Comply with New USP Chapters 41 and 1251 on Balances Used for Quantitative Analysis in the Pharma QC Lab
5. Elevation Pharmaceuticals Presents Positive Phase 2b Results for EP-101 in COPD Patients at the European Respiratory Society Annual Congress
6. Informex Global Pharma Sourcing 2012 Presents Key Strategies & Insight For Business Success
7. Epigenomics Presents Significant Opportunities for Investment and Product Development, According to New Biotech Market Research
8. Cardium Presents Second Quarter 2012 Financial Results And Reports On Recent Developments
9. Inovio Initiates H1N1 Universal Influenza Vaccine Clinical Trial Targeting Over-65 Population, Which Represents 90% of Flu Deaths
10. Grant & Eisenhofer Represents Key Whistleblower in Justice Dept.s $1.04 Billion Civil Settlement with GlaxoSmithKline
11. OncoSec Presents Preliminary Safety Data for Phase II Melanoma Study at Second European Post-Chicago Melanoma Meeting 2012
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/3/2015)... , August 3, 2015 ... by Persistence Market Research "Global Market Study on ... to Witness Highest Growth by 2022", the global physiotherapy ... Bn by the end of 2015 and is expected ... 2015 to 2022, to account for US$23.7 Bn by ...
(Date:8/3/2015)... 3, 2015  CytRx Corporation (NASDAQ: CYTR ), ... today reported financial results for the three months ended ... recent accomplishments and upcoming milestones for its clinical development ... been very productive for CytRx. Enrollment in our ongoing ... soft tissue sarcoma (STS) continues on track to be ...
(Date:8/3/2015)... 2015  Array BioPharma Inc. (NASDAQ: ARRY ... and full year of its fiscal year ended ... Executive Officer of Array, noted, "Binimetinib and encorafenib, two ... track for regulatory submissions in 2016. Additional data ... BRAF-mutant colorectal cancer further validate the value of ...
Breaking Medicine Technology:Global Physiotherapy Equipment Market Will Reach US$ 23.7 Billion by 2022: Persistence Market Research 2Global Physiotherapy Equipment Market Will Reach US$ 23.7 Billion by 2022: Persistence Market Research 3Global Physiotherapy Equipment Market Will Reach US$ 23.7 Billion by 2022: Persistence Market Research 4CytRx Reports 2015 Second Quarter Financial Results 2CytRx Reports 2015 Second Quarter Financial Results 3CytRx Reports 2015 Second Quarter Financial Results 4CytRx Reports 2015 Second Quarter Financial Results 5CytRx Reports 2015 Second Quarter Financial Results 6CytRx Reports 2015 Second Quarter Financial Results 7CytRx Reports 2015 Second Quarter Financial Results 8CytRx Reports 2015 Second Quarter Financial Results 9CytRx Reports 2015 Second Quarter Financial Results 10CytRx Reports 2015 Second Quarter Financial Results 11CytRx Reports 2015 Second Quarter Financial Results 12CytRx Reports 2015 Second Quarter Financial Results 13CytRx Reports 2015 Second Quarter Financial Results 14Array BioPharma Reports Financial Results For The Fourth Quarter And Full Year Of Fiscal 2015 2Array BioPharma Reports Financial Results For The Fourth Quarter And Full Year Of Fiscal 2015 3Array BioPharma Reports Financial Results For The Fourth Quarter And Full Year Of Fiscal 2015 4Array BioPharma Reports Financial Results For The Fourth Quarter And Full Year Of Fiscal 2015 5Array BioPharma Reports Financial Results For The Fourth Quarter And Full Year Of Fiscal 2015 6Array BioPharma Reports Financial Results For The Fourth Quarter And Full Year Of Fiscal 2015 7Array BioPharma Reports Financial Results For The Fourth Quarter And Full Year Of Fiscal 2015 8Array BioPharma Reports Financial Results For The Fourth Quarter And Full Year Of Fiscal 2015 9Array BioPharma Reports Financial Results For The Fourth Quarter And Full Year Of Fiscal 2015 10Array BioPharma Reports Financial Results For The Fourth Quarter And Full Year Of Fiscal 2015 11Array BioPharma Reports Financial Results For The Fourth Quarter And Full Year Of Fiscal 2015 12
... Feb. 10 Choosing foods bearing the organic label ... products they buy have been produced without the use of antibiotics, ... CBS Evening News with Katie Couric segment on livestock ... recognize and respect the powerful nature of antibiotics. As a result, ...
... , Evaluate Analgesic Efficacy and Safety ... Following Total Knee Replacement Surgery , SYDNEY ... QRxPharma Limited (ASX: QRX and OTCQX: QRXPY) announced ... (Study 009) to evaluate analgesic efficacy and safety of MoxDuo™IR, ...
Cached Medicine Technology:Organic Is Answer to Those Seeking Foods Produced Without Antibiotics 2Organic Is Answer to Those Seeking Foods Produced Without Antibiotics 3QRxPharma Initiates Second Pivotal Phase 3 Study of MoxDuo(TM)IR Dual-Opioid(TM) for NDA Submission 2QRxPharma Initiates Second Pivotal Phase 3 Study of MoxDuo(TM)IR Dual-Opioid(TM) for NDA Submission 3QRxPharma Initiates Second Pivotal Phase 3 Study of MoxDuo(TM)IR Dual-Opioid(TM) for NDA Submission 4QRxPharma Initiates Second Pivotal Phase 3 Study of MoxDuo(TM)IR Dual-Opioid(TM) for NDA Submission 5
(Date:8/4/2015)... , ... August 04, 2015 , ... The goal of ... though the desire for invasive surgery to achieve this ideal is not. But minimally ... people crave without the high cost or lengthy recovery time, according to Valerie ...
(Date:8/4/2015)... ... August 04, 2015 , ... Loyola University ... that its RN to BSN and Master of Science in Nursing in ... June 2020 from the Commission on Collegiate Nursing Education (CCNE), the ...
(Date:8/4/2015)... ... ... Nathan’s Famous was recently featured on NewsWatch as part of its monthly Biz ... their industry. Andrew Tropeano, the host of NewsWatch and business expert, conducted the business ... 50% Reduced Fat All-Beef Frank variety and is celebrating summer with Nathan’s Original ...
(Date:8/4/2015)... ... August 04, 2015 , ... Please join us for the 4th ... 20th at Oneida Shores Park in Brewerton, NY. , Doris Connor was a ... at the young age of 59. Her family and friends have since become steadfast ...
(Date:8/4/2015)... ... 04, 2015 , ... IN AMERICA and the program's host, ... Depression affects millions of Americans every single year. To help people obtain a ... with the latest segment produced with the assistance of several top medical professionals. ...
Breaking Medicine News(10 mins):Health News:Considering fillers, tighteners or laser resurfacing? 2Health News:Considering fillers, tighteners or laser resurfacing? 3Health News:Considering fillers, tighteners or laser resurfacing? 4Health News:Loyola University New Orleans Awarded Accreditation for its Online RN to BSN and MSN Programs 2Health News:Loyola University New Orleans Awarded Accreditation for its Online RN to BSN and MSN Programs 3Health News:Loyola University New Orleans Awarded Accreditation for its Online RN to BSN and MSN Programs 4Health News:Celebrate Summer with Nathan’s Famous Original Selfie Sweepstakes 2Health News:Celebrate Summer with Nathan’s Famous Original Selfie Sweepstakes 3Health News:4th Annual Doris A. Connor Memorial Event for Brain Aneurysm Awareness to be Held in Brewerton, NY with Proceeds Benefitting Renowned Brain Aneurysm Foundation 2Health News:4th Annual Doris A. Connor Memorial Event for Brain Aneurysm Awareness to be Held in Brewerton, NY with Proceeds Benefitting Renowned Brain Aneurysm Foundation 3
... IRVINE, Calif., Nov. 3 Endologix, Inc. (Nasdaq: ELGX ), ... John McDermott, President and Chief Executive Officer, is scheduled to present ... at the Canaccord Adams 3rd Annual Cardiovascular Conference at the Nikko ... Event: Canaccord Adams 3rd Annual Cardiovascular ...
... the same holds true for humans, researchers say , TUESDAY, Nov. ... sweet life may also be the short life. , New research ... 20 percent of their life span. , It,s unclear what ... impact of diets high in sugar, according to the study authors, ...
... is also a prescription for self-esteem among breast cancer ... Medicine research. Breast cancer survivors who lift weights regularly ... more satisfied with their intimate relationships compared with survivors ... study published in the journal Breast Cancer Research ...
... ... in Jackson, Miss. has started posting surgical videos as part of a new section ... surgery to correct sunken chest syndrome in pediatric patients. As part the new portion ... unique procedure by way of video. , ...
... 3 Triple-S Management Corporation (NYSE: GTS ), the ... revenues of $507.3 million and operating income of $15.4 million ... of $18.1 million, or $0.62 per diluted share, includes an ... share, in net realized and unrealized gains on investments and ...
... claims and risk management provider Avizent announced today the introduction ... medical experts are involved in workers, compensation claims from day ... the new service is to safely return injured employees to ... workers, comp claims. Avizent is one of only a few ...
Cached Medicine News:Health News:Endologix to Present at Three Upcoming Conferences 2Health News:Sugar Shortens Life Span in Worms 2Health News:Weight training boosts breast cancer survivors' body image and intimate relationship satisfaction 2Health News:New Video Post Shows Minimally Invasive Procedure To Correct Sunken Chest Syndrome 2Health News:Triple-S Management Corporation Reports Third Quarter 2009 Results 2Health News:Triple-S Management Corporation Reports Third Quarter 2009 Results 3Health News:Triple-S Management Corporation Reports Third Quarter 2009 Results 4Health News:Triple-S Management Corporation Reports Third Quarter 2009 Results 5Health News:Triple-S Management Corporation Reports Third Quarter 2009 Results 6Health News:Triple-S Management Corporation Reports Third Quarter 2009 Results 7Health News:Triple-S Management Corporation Reports Third Quarter 2009 Results 8Health News:Triple-S Management Corporation Reports Third Quarter 2009 Results 9Health News:Triple-S Management Corporation Reports Third Quarter 2009 Results 10Health News:Triple-S Management Corporation Reports Third Quarter 2009 Results 11Health News:Triple-S Management Corporation Reports Third Quarter 2009 Results 12Health News:Triple-S Management Corporation Reports Third Quarter 2009 Results 13Health News:Triple-S Management Corporation Reports Third Quarter 2009 Results 14Health News:Triple-S Management Corporation Reports Third Quarter 2009 Results 15Health News:Triple-S Management Corporation Reports Third Quarter 2009 Results 16Health News:Avizent's New TeamCOMP Approach Helps Ensure Lower Workers' Comp Costs and Faster Claims Resolution 2
The TAXUS Express Paclitaxel-Eluting Coronary Stent System is indicated for improving luminal diameter for the treatment of de novo lesions = 28 mm in length in native coronary arteries = 2.5 to = 3....
... Maximum, Maximum Xtra, and Maximum ACT ... standard and specialty hemostasis introducers in ... the premier hemostasis introducers for use ... including angiography, angioplasty, stenting, atherectomy, temporary ...
St. Jude Medical's line of guiding introducers includes Swartz Series, SAFL, SEPT, CSTA, RAMP, and 2 piece steerable...
Rapid Exchange Stent Delivery System with Hepacoat...
Medicine Products: